1 |
Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X (2009) Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 113: 893-901
DOI
|
2 |
Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ, Jakubowski JA (1996) p38 mitogenactivated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombinstimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271: 27723-27729
DOI
|
3 |
McNicol A, Shibou TS (1998) Translocation and phosphorylation of cytosolic phospholipase A2 in activated platelets. Thromb Res 92: 19-26
DOI
|
4 |
Chuang WY, Kung PH, Kuo CY, Wu CC (2013) Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway, Thromb. Haemost 109(6): 1120-1130
DOI
|
5 |
Huang HC, Chu SH, Chao PD (1991) Vasorelaxants from Chinese herbs, emodin and scoparone, possess immunosuppressive properties. Eur J Pharmacol 198: 211-213
DOI
|
6 |
Huang HC, Lee CR, Weng YI, Lee MC, Lee YT (1992) Vasodilator effect of scoparone (6,7-dimethoxycoumarin) from a Chinese herb. Eur J Pharmacol 218: 123-128
DOI
|
7 |
Lu C, Li Y, Hu S, Cai Y, Yang Z, Peng K (2018) Scoparone prevents IL--induced inflammatory response in human osteoarthritis chondrocytes through the PI3K/Akt/NF- pathway. Biomed Pharmacother 106: 1169-1174
DOI
|
8 |
Lee DH (2019) Antiplatelet effects of scoparone through up-regulation of cAMP and cGMP on U46619-induced human platelets. J Appl Biol Chem 62: 425-431
DOI
|
9 |
Shin JH, Kwon HW, Lee DH (2019) Ginsenoside F4 inhibits platelet aggregation and thrombus formation by dephosphorylation of IP3RI and VASP. J Appl Biol Chem 62: 93-100
DOI
|
10 |
Chang MC, Wang TM, Yeung SY, Jeng PY, Liao CH, Lin CC, Lin BR, Jeng JH (2011) Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis 219(2): 559-565
DOI
|
11 |
Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96: 1109-1116
DOI
|
12 |
Patrono C (2001) Aspirin: new cardiovascular uses for an old drug. Am J Med 110: 62S-65S
DOI
|
13 |
Irfan M, Jeong D, Saba E, Kwon HW, Shin JH, Jeon BR, Kim S, Kim SD, Lee DH, Nah SY, Rhee MH (2019) Gintonin modulates platelet function and inhibits thrombus formation via impaired glycoprotein VI signaling. Platelets 30(5): 589-598
DOI
|
14 |
McNicol A, Jackson EC (2003) Inhibition of the MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets. Biochem Pharmacol 65(8): 1243-1250
DOI
|
15 |
Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H (2000) The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 60(8): 1069-1074
DOI
|
16 |
Morello F, Perino A, Hirsch E (2009) Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 82(2): 261-271
DOI
|
17 |
Jackson SP (2011) Arterial thrombosis--insidious, unpredictable and deadly. Nat Med 17: 1423-1436
DOI
|
18 |
Schwartz SM, Heimark RL, Majesky MW (1990) Developmental mechanisms underlying pathology of arteries. Physiol Rev 70: 1177-1209
DOI
|
19 |
Sabatine MS, Jang IK (2000) The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 109(3): 224-237
DOI
|
20 |
Jennings LK (2009) Role of platelets in atherothrombosis. Am J Cardiol 103: 4A-10A
DOI
|
21 |
Cattanco M, Tenconi PM, Lecchi A, Mannucci PM (1991) In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res 62: 717-724
DOI
|
22 |
Su CY, Shiao MS, Wang CT (1999) Differential effects of ganodermic acid S on the thromboxane A2-signaling pathways in human platelets. Biochem Pharmacol 58: 587-595
DOI
|
23 |
Adam F, Kauskot A, Rosa JP, Bryckaert M (2008) Mitogenactivated protein kinases in hemostasis and thrombosis. J Thromb Haemost 6: 2007-2016
DOI
|
24 |
Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M (1990) Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 94: 3800-3805
DOI
|
25 |
Kramer RM, Roberts EF, Strifler BA, Johnstone EM (1995) Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 270: 27395-27398
DOI
|
26 |
Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Bryckaert M (2002) Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 531: 475-482
DOI
|
27 |
Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330: 1287-1294
DOI
|